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Extended Application of
Percutaneous Pulmonary Valve Implantation
Tarek S. Momenah, MD,* Reida El Oakley, MD,* Khalid Al Najashi, MD,* Saad Khoshhal, MD,*
Howaida Al Qethamy, MD,* Philipp Bonhoeffer, MD†
Riyadh, Saudi Arabia; and London, United Kingdom
Objectives This study was designed to report a novel indication for percutaneous pulmonary valve implantation in patients
with previous right ventricular outflow tract (RVOT) patch.
Background Current indications for percutaneous pulmonary valve implantation are limited to patients who had pulmonary
valve stenosis and/or regurgitation in a right ventricle-to-pulmonary artery conduit. Percutaneous pulmonary
valve implantation has not been previously reported in patients with severe pulmonary valve regurgitation
following repair of tetralogy of Fallot (TOF) using RVOT patch.
Methods After assessment of the RVOT patch in multiple projections, a catheter was placed in a distal pulmonary artery
branch. In patients with an RVOT patch, sizing of the narrowest diameter of the RVOT patch by manual inflation of a
sizing balloon was performed; a stent was placed into the RVOT patch at the level of the narrowest area to anchor the
stent and to create an artificial conduit to place the Melody valve. The percutaneous valve was then implanted.
Results Seven females and 6 males with a mean age of 14.3 years and mean body weight 45 kg had successful percu-
taneous implantation of the Melody valve. Four patients had previous repair of TOF using RVOT patch. All pa-
tients were discharged within 2 days after the procedure without complications. After a mean of 4 months
follow-up all patients were alive and well. Transthoracic echocardiography showed competent pulmonary valve.
Chest X-ray showed no stent migration or fracture.
Conclusions Percutaneous pulmonary valve implantation can be performed in patients with pulmonary valve regurgitation,
including those with previous RVOT patch using pre-stenting techniques, with satisfactory results. (J Am Coll
Cardiol 2009;53:1859–63) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.061e
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vecent reports suggest that pulmonary valve replacement for
hronic pulmonary valve regurgitation (PVR) should be
onsidered before impairment of right ventricular (RV)
unction (1). This is particularly true for patients who have
ad chronic PVR following a right ventricular outflow tract
RVOT) patch for tetralogy of Fallot (TOF) repair. How-
ver, the invasive nature of redo PVR with its attendant risk
ay deter patients and their physicians from considering
arlier valve replacement. The introduction of percutaneous
ulmonary valve implantation (PPVI) to the clinical arena
ay quickly enable the reversal of this thinking process. To
ate, there is no report of use of this novel technology in
atients who have had previous TOF repair using the
VOT patch (2,3). Moreover, the RVOT patch was con-
idered a relative contraindication to PPVI in the early
rom the *Department of Pediatric Cardiology, Prince Sultan Cardiac Center,
iyadh, Saudi Arabia; and the †Cardiac Unit, Great Ormond Street Hospital for
hildren, London, United Kingdom. Dr. El Oakley has previously worked as a
onsultant for Medtronic, Inc., and Dr. Bonhoeffer works as a consultant fors
edtronic, Inc.
Manuscript received June 18, 2008; accepted August 13, 2008.xperience of Khambadkone et al. (2,3). We report PPVI in
3 patients, including 4 patients with pulmonary valve
egurgitation after previous TOF repair using an RVOT
atch.
ethods
etween September 2007 and March 2008, a total of 15
atients were referred for pulmonary valve implantation.
wo patients were excluded from the study for technical
easons. The demographics of the 13 patients who had the
omplete procedure are summarized in Table 1.
All procedures were performed under general anesthesia.
ardiac catheterization was performed via percutaneous
uncture of the right femoral vein. The femoral artery was
lso percutaneously accessed for monitoring and simulta-
eous coronary angiogram to rule out any potential com-
ression on the coronary arteries by the newly implanted
alve.
After assessment of the RVOT in multiple projections, a
uper-stiff exchange guidewire (Back-up Meier, Boston Scien-
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tioned in a distal pulmonary artery
(PA) branch using a right coronary
catheter. This was followed by siz-
ing of the narrowest diameter of
the outflow tract by manual infla-
tion of a 24-mm sizing balloon
(AGA Medical Corporation,
Golden Valley, Minnesota), to de-
termine its suitability for PPVI. In
patients with previous conduits,
the annulus size was determined
by the original size of conduit. In
patients with an RVOT patch, the
ean size of annulus was 18 mm, and the stretch diameter was
0 mm.
Five of 6 patients with an RVOT patch had the RVOT
atch extending into the main PAs (i.e., transannular
atch); in these patients, a stent was placed into the RVOT
t the level of the narrowest area to anchor the stent to
reate what we call an artificial conduit.
The stents were selected to cover most of the RVOT.
he stents were deployed so that one-third of the stent fell
elow the RVOT narrowest diameter, with the intent to
eep the upper end of the stent 5 to 10 mm below the
ifurcation of the main PA (Fig. 1). Three of 4 patients had
34-mm-long CP stent (NuMED, Inc., Hopkinton, New
ork). In 1 patient, a 36-mm intrastent LD max (ev3 Inc.,
lymouth, Minnesota) was used. All were pre-mounted on
22 40 mm balloon-in-balloon catheter (NuMED, Inc.).
The Melody valve (Medtronic Inc., Minneapolis, Min-
esota) was prepared using the ensemble delivery system as
reviously described (2,4). In summary, the Melody valve
as withdrawn fully into a protective sheath on the delivery
ystem. The whole assembly was then passed over the
uidewire and advanced into the pre-stented RVOT patch
r the stenotic conduit. Once in an acceptable position, the
overing sheath was withdrawn to expose the Melody valve
Abbreviations
and Acronyms
PA  pulmonary artery
PPVI  percutaneous
pulmonary valve
implantation
PVR  pulmonary valve
regurgitation
RV  right ventricular
RVOT  right ventricular
outflow tract
TOF  tetralogy of Fallot
atient Demographics and Diagnoses
Table 1 Patient Demographics and Diagnoses
Patient # Sex
Age
(yrs)
Weight
(kg)
Height
(cm)
Body Surface
Area (m2)
1 Female 15 75 160 1.6 Pulmonary atr
2 Female 17 61 157 1.61 Truncus arteri
3 Male 19 49 176 1.60 Pulmonary atr
4 Male 12 34 157 1.21 TOF, post repa
5 Female 12 34 130 1.11 Pulmonary atr
6 Female 10 37 138 1.19 TOF, repaired
7 Male 17 60 156 1.6 TOF, repaired
8 Female 11 30 133 1.05 TOF, repaired
9 Female 13 49 148 1.40 TOF, repaired
10 Male 11 40 141 1.25 D-transpositio
11 Male 11 36 148 1.24 Pulmonary atr
12 Female 23 30 145 1.12 TOF, repaired
13 Male 15 84 166 1.92 TOF, repairedVOT  right ventricular outflow tract; RV-PA  right ventricle-pulmonary artery; TOF  tetralogy of Fallohat was previously crimped on the balloon. The inner and
uter balloons were sequentially inflated, thus deploying the
elody valve. Thereafter, both balloons were rapidly de-
ated and removed, leaving the guidewire in place. Angio-
raphic and hemodynamic evaluations were repeated before
he guidewire was finally removed.
The procedure could not be completed in the 2 patients
ho proved to be unsuitable for the procedure because their
VOT patch stretch diameter was 22 mm, which was
arger than the size of the Melody valve available.
Patients were assessed on day 1, as well as 1, 3, and 6
onths after the procedure. Assessment included physical
xamination, 12-lead electrocardiography, chest X-rays
posterior anterior and lateral views), and cross-sectional
chocardiography with color Doppler.
tatistical analysis. Descriptive data are presented as
ean  SD. A paired Student t test was used to compare
he before- and after-PPVI data. A p value of 0.05 was
onsidered significant, and statistical analysis was performed
sing SPSS (SPSS Inc., Chicago, Illinois).
esults
even females and 6 males, age range 10 to 23 years (mean
4.3 years), weight range 30 to 84 kg (mean 45 kg), had
uccessful PPVI (Table 1). Most of the patients had variant
OF, and the majority of them were treated with RV-
o-PA valve conduits. Only 4 patients (numbers 1, 7, 8, and
3 in Table 1) had a previous surgical repair using an
VOT patch. The median procedure time was 102 min
rom puncture to sheath removal (range 67 to 124 min), and
edian fluoroscopy time was 21 min (range 11 to 36 min).
After valve implantation, the RV systolic pressure
ropped from 61.2  14.9 mm Hg to 37.6  6.7 mm Hg
p  0.05). The outflow (RV-PA) pressure gradient was
lso reduced from 39.6  15.1 mm Hg to 12.1  9 mm
Diagnosis
ith VSD, repaired with RVOT patch with transannular patch
post–re-do conduit replacement with 20-mm Hancook valved conduit
ith VSD, repaired with 20-mm Hancook valved conduit
ith 18-mm Hancook valved conduit
ith VSD, repaired with 22-mm Hancook valved conduit
2-mm Hancook valved conduit
VOT patch with pulmonary valvotomy
VOT patch with transannular patch
1-mm Hancook valved conduit
e great arteries post-Rastelli operation with RV-PA Hancook 20-mm valved conduit
ith VSD, repaired with 19-mm valved conduit
ancook 18-mm valved conduit
VOT patch with transannular patchesia w
ousus,
esia w
ired w
esia w
with 2
with R
with R
with 2
n of th
esia w
with H
with Rt; VSD  ventricular septal defect.
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May 19, 2009:1859–63 Novel Use of Percutaneous Pulmonary ValveFigure 1 Lateral View of the RV Outflow Patch
(A) Lateral view of a still-frame angiogram of the right ventricular (RV) outflow
patch with severe pulmonary regurgitation. (B) As in A after pre-stenting.
(C) Same patient shown in A and B following percutaneous pulmonary valve
implantation, showing a competent valve.Figure 2 Changes in Ventricular Systolic Pressure,
Pulmonary Valve Gradient, and PA Diastolic Pressure
Changes in (A) right ventricular (RV) systolic pressure, (B) pulmonary valve gra-
dient, and (C) pulmonary artery (PA) diastolic pressure before and after percu-
taneous pulmonary valve implantation (PPVI).
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Novel Use of Percutaneous Pulmonary Valve May 19, 2009:1859–63g (p  0.05). PA diastolic pressure increased from 8.1
2.6 mm Hg to 11.5  2.8 mm Hg (p  0.05) (Fig. 2).
mmediately after implantation, angiography showed no
atient with more than mild regurgitation. Furthermore,
here was a trend toward reduction in the RV end-
iastolic pressure; however, this did not reach statistical
ignificance (data not shown).
Echocardiography performed 24 h after the PPVI
howed a reduction in RV systolic pressure as estimated
rom tricuspid valve regurgitation velocity and RVOT
radient. There was also a reduction in the PVR grade,
nd all patients had no or trace PVR after the procedure
Fig. 3).
Figure 3 Continuous-Wave Doppler Tracing of the Pulmonary Va
(Top) Pulmonary regurgitation before pulmonary valve implantation; (bottom) compAll patients were discharged within 2 days after the
rocedure. The mean follow-up was 4 months, and all
atients were alive and well. There were no immediate or
ate complications.
During follow-up, serial echocardiography showed that
n early decrease in the RVOT gradient was sustained at the
atest follow-up. Chest X-rays, posterior-anterior and lateral
iews, showed no stent migration or fracture.
iscussion
e have shown that PPVI can be used in patients with
hronic PVR in the presence of an RVOT patch. However,
pulmonary valve following percutaneous pulmonary valve implantation.lve
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ntravascular stent as an artificial conduit that allows subse-
uent valve implantation.
Gibbs et al. (5) have previously described stenting of the
VOT as palliative for severe RV infundibular stenosis as
n alternative to surgical ventricular outflow enlargement.
e have modified this technique to allow the use of a stent
s an artificial conduit to anchor the Melody valve.
This technique can be applied to patients with an RVOT
imension of 22 mm because the maximum available size
f the Melody valve is 22 mm. We expect that the use of a
onger stent in the RVOT will not only facilitate implanting
he pulmonary valve but may also prevent stent fracture
nd/or migration of the newly implanted pulmonary valve.
Pre-dilation of the stenotic area is an important step for
afety and effectiveness in pre-stenting an RVOT patch.
ompliance of the RVOT patch is unpredictable, but
alloon sizing allows for determination of the exact location
f the waist. The presence of multiple waists may result in
tent malposition. Furthermore, balloon sizing may predict
otential coronary artery compression if performed with
imultaneous coronary angiography. This potential compli-
ation has been previously described (6). Because the
VOT patch is relatively more distensible as compared to
onduits, we elected to use the more compliant AGA
alloon.
These preliminary results suggest that, in selected pa-ients, pre-stenting and pulmonary valve implantation offers
K
Fless invasive alternative to re-do surgical operation in
atients after TOF repair with an RVOT patch. However,
urther follow-up is required to study the long-term results
f PPVI in this subset of patients.
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